Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Adagio Medical Holdings (ADGM) EBITDA (2023 - 2025)

Adagio Medical Holdings (ADGM) has disclosed EBITDA for 3 consecutive years, with -$3.3 million as the latest value for Q4 2025.

  • Quarterly EBITDA changed N/A to -$3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$25.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$25.2 million for FY2025, N/A changed from the prior year.
  • EBITDA for Q4 2025 was -$3.3 million at Adagio Medical Holdings, up from -$10.1 million in the prior quarter.
  • The five-year high for EBITDA was $3.6 million in Q3 2024, with the low at -$10.8 million in Q3 2023.
  • Average EBITDA over 3 years is -$6.1 million, with a median of -$7.8 million recorded in 2025.
  • The sharpest move saw EBITDA soared 133.44% in 2024, then tumbled 381.18% in 2025.
  • Over 3 years, EBITDA stood at -$8.6 million in 2023, then surged by 141.68% to $3.6 million in 2024, then tumbled by 192.02% to -$3.3 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$3.3 million, -$10.1 million, and -$4.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.